A Study of Personalized Molecular Markers to Transform Treatment of High Grade Endometrial Cancer

Overview

About this study

The purpose of this study is to characterize a landscape of DNA alterations, RNA transcripts, and microbiome changes in resected tumors and body fluids of patients that have been diagnosed with aggressive endometrial cancer (Grade 3 and Type II) in order to identify molecular targets for which therapeutic drugs may exist.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:  

  • Women age ≥ 18 years.
  • Biopsy-proven high-grade endometrial cancer.
  • Biopsy histology is Grade 3 endometrioid, serous, clear cell, poorly differentiated, or undifferentiated.
  • Scheduled to undergo hysterectomy at Mayo Clinic.
  • Willing to complete follow-up serial blood samples post-operatively.
  • Willing and able to provide signed informed consent.

Exclusion Criteria: 

  • Biopsy histology is Grade 1 or Grade 2 endometrioid.
  • Change in planned surgical procedure such that hysterectomy is not performed at Mayo Clinic.
  • Tumor quantity or cell viability expected to not be sufficient for the study analyses.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Andrea Mariani, M.D., M.S.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Matthew Robertson, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Paul Magtibay, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions